Cargando…

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report

Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-Montoro, José Ignacio, Pinzón-Martín, José Luis, Damas-Fuentes, Miguel, Fernández-Valero, Andrea, Tinahones, Francisco J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046779/ https://www.ncbi.nlm.nih.gov/pubmed/35498407 http://dx.doi.org/10.3389/fendo.2022.838887

Ejemplares similares

Role of the Gut Microbiome in Beta Cell and Adipose Tissue Crosstalk: A Review
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2023)

25-hydroxyvitamin D and testosterone levels association through body mass index: A cross-sectional study of young men with obesity
por: Damas-Fuentes, Miguel, et al.
Publicado: (2022)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

Obesity‐related glomerulopathy: Current approaches and future perspectives
por: Martínez‐Montoro, José Ignacio, et al.
Publicado: (2022)

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
por: García de Lucas, María Dolores, et al.
Publicado: (2023)

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2022)

“Triple-negative” non-secretory medullary thyroid cancer: uncommon pathological findings in a rare disease
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy
por: Bai, Zhenyu, et al.
Publicado: (2022)

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2019)

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
por: Zhu, Ruiyi, et al.
Publicado: (2023)

Corrigendum: Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2020)

Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model
por: Yang, Mei, et al.
Publicado: (2020)

Malignant mixed Müllerian tumour of the uterus associated with non-islet cell tumour hypoglycaemia
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2021)

Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report
por: Gupta, Sushan, et al.
Publicado: (2023)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
por: Brown, Emily, et al.
Publicado: (2021)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Interaction Among Sex, Aging, and Epigenetic Processes Concerning Visceral Fat, Insulin Resistance, and Dyslipidaemia
por: Arpón, Ana, et al.
Publicado: (2019)

Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis
por: El-Shafey, Mohamed, et al.
Publicado: (2022)

Secondary male hypogonadism: a prevalent but overlooked comorbidity of obesity
por: Molina-Vega, María, et al.
Publicado: (2018)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Irisin, in women and men: blood pressure, heart rate, obesity and insulin resistance
por: Almeida González, Delia, et al.
Publicado: (2023)

An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
por: Dagli, Namrata, et al.
Publicado: (2023)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
por: Li, Yinhui, et al.
Publicado: (2022)

Editorial: Insulin and The Brain
por: Taouis, Mohammed, et al.
Publicado: (2019)

Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
por: Volpe, Sara, et al.
Publicado: (2023)

Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
por: Iqbal, Iqra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_757cbrr7gu2n1apvuc9do2mclp